The present disclosure is generally directed to treatment methods and compositions comprising administering anti-SSEA-4 antibodies； alone or in additive and/or synergistic combination with other therapeutic agents in oncology to enhance therapeutic efficacy whereby the interaction alters the epitope binding of Siglec-9 protein； including human Siglec-9 or a mammalian Siglec-9； wherein the use of such anti-SSEA-4 compositions are efficacious in preventing, reducing risk, or treating an individual with cancer.
